8622 — Huakang Biomedical Holdings Co Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$51.05m
- HK$17.91m
- CNY24.63m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | — |
Source: | ARS | ARS | ARS | ARS | |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Net Income/Starting Line | 0.658 | -11.4 | -3.9 | -3.01 | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | -0.443 | 5.9 | 0.433 | 0.057 | — |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -6.37 | -1.65 | -1.86 | 1.1 | — |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -3.39 | -3.92 | -2.38 | 1.29 | — |
Capital Expenditures | -2.21 | -2.08 | -2.33 | -0.811 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.184 | 0.145 | 0.276 | -5.3 | — |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2.02 | -1.94 | -2.06 | -6.11 | — |
Financing Cash Flow Items | 0 | — | 0.101 | 1.31 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.594 | -1.11 | -1.37 | 2.32 | — |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -6 | -6.85 | -5.74 | -2.9 | — |